

August 8, 2013



XOMA to Present at Two Upcoming Investor Conferences

BERKELEY, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today members of its executive team will present at two upcoming investor conferences. The details are as follows:

- 2013 Wedbush Life Sciences Management Access Conference on Tuesday, August 13, at 3:05 p.m. ET
- Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14, at 1:30 p.m. ET

Live audio webcasts of the presentations can be accessed through the Investors and Media section of XOMA's website at <http://investors.xoma.com/events.cfm>. Archived versions of the webcast will be available via replay for 30 days following the presentation.

About XOMA Corporation

XOMA's portfolio of innovative product candidates is the result of the Company's focus on allosteric modulation, which offers opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.

More detailed information can be found at www.xoma.com.

CONTACT: Company and Investor Contacts:

Ashleigh Barreto
510-204-7482
barreto@xoma.com

Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com

Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375

carolyn@canalecomm.com

Source: XOMA Corporation